-

SQZ Biotech to Participate in June Investor Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief executive officer, will be presenting at the following upcoming virtual investor conferences:

Jefferies Virtual Healthcare Conference
Tuesday, June 2, 2020
Presentation Time: 3:30pm-3:55pm ET

Raymond James Human Health Innovations Conference
Wednesday, June 17, 2020
Cell Therapy Panel Time: 12:00pm ET

Dr. Sharei and Teri Loxam, chief financial officer will also be holding one on one meetings during the conferences.

About SQZ Biotech

SQZ Biotech is a privately held clinical stage company developing transformative cell therapy candidates for patients with cancer and other serious diseases. Our proprietary approach to cell engineering, Cell Squeeze®, physically squeezes cells through a microfluidic constriction to temporarily disrupt the cell membrane, allowing desired cargo to diffuse into the cell cytosol before the membrane reseals. We use this approach to deliver a broad range of biological material into diverse cell types to create multifunctional cell therapy candidates designed to direct specific immune responses. We believe Cell Squeeze® technology may allow us to create rapidly scalable cell therapies that leverage natural physiology to improve therapeutic efficacy with favorable safety and tolerability. The SQZ technology could provide treatment options with advantages for patients across many diseases. For more information please visit www.sqzbiotech.com.

Contacts

SQZ:
Rebecca Cohen
Corporate and Investor Relations
rebecca.cohen@sqzbiotech.com
617-758-8672 ext. 728

Media:
Kate Contreras
Associate Director
kcontreras@w2ogroup.com
617-229-5960

SQZ Biotechnologies


Release Versions

Contacts

SQZ:
Rebecca Cohen
Corporate and Investor Relations
rebecca.cohen@sqzbiotech.com
617-758-8672 ext. 728

Media:
Kate Contreras
Associate Director
kcontreras@w2ogroup.com
617-229-5960

More News From SQZ Biotechnologies

SQZ Biotechnologies Reports 2020 Financial Results and Recent Advancements

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today reported full year 2020 financial results and recent business highlights. “In 2020, we experienced the most important moment in SQZ’s journey so far: dosing our first patient. This accomplishment was coupled with exciting progress across our pipeline and the transition to being a public company. Despite the many challenges of COVID-19, our...

SQZ Biotech Announces Proposed Public Offering of Common Stock

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that it has commenced an underwritten public offering of 3,000,000 shares of common stock. All of the shares of common stock are being offered by SQZ. In addition, SQZ expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of its common stock at the public offering price, l...

SQZ Biotechnologies Announces FDA Clearance of IND Application to Allow for Clinical Trial with SQZ Activating Antigen Carriers (SQZ AACs) in Patients with HPV+ Tumors

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that the company’s Investigational New Drug (IND) application for SQZTM Activating Antigen Carriers (SQZ AACs) in HPV+ tumors was cleared by the U.S. Food and Drug Administration (FDA). The clinical trial will investigate SQZ-AAC-HPV, a cell therapy candidate generated from red blood cells (RBCs) engineered with tumor-specific ant...
Back to Newsroom